Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

mAbs

Showing results (1331-1340 of 1,779) with videos related to

Pageof 178
Sort By:
Mabs|April 26, 2012
Insights from Fc receptor biology: a route to improved antibody reagentsJenny M Woof
Mabs|April 26, 2012
Lepidopteran cells, an alternative for the production of recombinant antibodies?Martine Cérutti, Josée Golay
Mabs|April 26, 2012
Marketed therapeutic antibodies compendiumJanice M Reichert
Mabs|April 26, 2012
The birth pangs of monoclonal antibody therapeutics: the failure and legacy of CentoxinLara Marks
Mabs|April 26, 2012
Galactosylation variations in marketed therapeutic antibodiesT Shantha Raju, Robert E Jordan
Mabs|April 26, 2012
Impact of linker and conjugation chemistry on antigen binding, Fc receptor binding and thermal stability of model antibody-drug conjugatesMauro Acchione, Hyewon Kwon, Claudia M Jochheim, et al.
Mabs|June 7, 2012
Increased serum clearance of oligomannose species present on a human IgG1 moleculeLeslie Alessandri, David Ouellette, Aima Acquah, et al.
Mabs|September 19, 2015
Development of human-like scFv-Fc antibodies neutralizing Botulinum toxin serotype BChristine Rasetti-Escargueil, Arnaud Avril, Siham Chahboun, et al.
Mabs|April 1, 2016
Preclinical pharmacokinetics of MHAA4549A, a human monoclonal antibody to influenza A virus, and the prediction of its efficacious clinical dose for the treatment of patients hospitalized with influenza APriyanka Gupta, Amrita V Kamath, Summer Park, et al.
Mabs|May 24, 2016
A comparison of biophysical characterization techniques in predicting monoclonal antibody stabilityGeetha Thiagarajan, Andrew Semple, Jose K James, et al.
Pageof 178

Showing results (1331-1340 of 1,779) with videos related to

Sort By:
Pageof 178
Mabs|April 26, 2012
Insights from Fc receptor biology: a route to improved antibody reagentsJenny M Woof
Mabs|April 26, 2012
Lepidopteran cells, an alternative for the production of recombinant antibodies?Martine Cérutti, Josée Golay
Mabs|April 26, 2012
Marketed therapeutic antibodies compendiumJanice M Reichert
Mabs|April 26, 2012
The birth pangs of monoclonal antibody therapeutics: the failure and legacy of CentoxinLara Marks
Mabs|April 26, 2012
Galactosylation variations in marketed therapeutic antibodiesT Shantha Raju, Robert E Jordan
Mabs|April 26, 2012
Impact of linker and conjugation chemistry on antigen binding, Fc receptor binding and thermal stability of model antibody-drug conjugatesMauro Acchione, Hyewon Kwon, Claudia M Jochheim, et al.
Mabs|June 7, 2012
Increased serum clearance of oligomannose species present on a human IgG1 moleculeLeslie Alessandri, David Ouellette, Aima Acquah, et al.
Mabs|September 19, 2015
Development of human-like scFv-Fc antibodies neutralizing Botulinum toxin serotype BChristine Rasetti-Escargueil, Arnaud Avril, Siham Chahboun, et al.
Mabs|April 1, 2016
Preclinical pharmacokinetics of MHAA4549A, a human monoclonal antibody to influenza A virus, and the prediction of its efficacious clinical dose for the treatment of patients hospitalized with influenza APriyanka Gupta, Amrita V Kamath, Summer Park, et al.
Mabs|May 24, 2016
A comparison of biophysical characterization techniques in predicting monoclonal antibody stabilityGeetha Thiagarajan, Andrew Semple, Jose K James, et al.
Pageof 178